Endocannabinoid binding to the cannabinoid receptors: What is known and what remains unknown

Current Medicinal Chemistry

Volumn 17, Issue 14, 2010, Pages 1468-1486

  Reggio, Patricia H ^a  

^a UNIVERSITY OF NORTH CAROLINA AT GREENSBORO   (United States)

Author keywords

2 AG; Anandamide; Cannabinoid; Endocannabinoid; GPCR; Molecular dynamics; Mutation; QSAR

Indexed keywords

1 (2,4 DICHLOROPHENYL) 5 (4 IODOPHENYL) 4 METHYL N (1 PIPERIDYL) 1H PYRAZOLE 3 CARBOXAMIDE; 2 ARACHIDONOYLGLYCEROL; 2,3 DIHYDRO 5 METHYL 3 (MORPHOLINOMETHYL) 6 (1 NAPHTHOYL)PYRROLO[1,2,3 DE][1,4]BENZOXAZINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 [6 METHOXY 2 (4 METHOXYPHENYL) 3 BENZOFURANYLCARBONYL]BENZONITRILE; 5 (4 CHLORO 3 METHYLPHENYL) 1 (4 METHYLBENZYL) N (1,3,3 TRIMETHYLBICYCLO[2.2.1]HEPTAN 2 YL) 3 PYRAZOLECARBOXAMIDE; ADENOSINE 5' O (3 THIOTRIPHOSPHATE); ANANDAMIDE; ARACHIDONIC ACID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; CANNABINOID 2 RECEPTOR; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; CP 272871; CYCLOOXYGENASE 2; DEXANABINOL; DRONABINOL; ENDOCANNABINOID; G PROTEIN COUPLED RECEPTOR; LIPOPROTEIN LIPASE; METHANANDAMIDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; NOLADIN ETHER; O 1184; PHOSPHATIDYLINOSITOL 3 KINASE; RIMONABANT; UNCLASSIFIED DRUG; UNINDEXED DRUG; URB 447; VIRODHAMINE;

COMPUTER SIMULATION; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; HUMAN; MOLECULAR DOCKING; MOLECULAR DYNAMICS; MOLECULAR INTERACTION; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; NUCLEOTIDE SEQUENCE; QUANTITATIVE STRUCTURE ACTIVITY RELATION; RECEPTOR AFFINITY; REVIEW;

ARACHIDONIC ACIDS; ENDOCANNABINOIDS; GLYCERIDES; MOLECULAR DYNAMICS SIMULATION; POLYUNSATURATED ALKAMIDES; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; RECEPTORS, CANNABINOID;

EID: 77950646343     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710790980005     Document Type: Review

References (211)

1. Matsuda, L.A.; Lolait, S.J.; Brownstein, M.J.; Young, A.C.; Bonner, T.I. Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature, 1990, 346, 561-564 (Pubitemid 20238806)
2. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Mansouri, J.; Mackie, K.; Blond, O.; Lai, Y.; Ma, A.L.; Mitchell, R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol., 1995, 48, 443-450
3. Mackie, K.; Lai, Y.; Westenbroek, R.; Mitchell, R. Cannabinoids activate an inwardly rectifying potassium conductance and inhibit Q-type calcium currents in AtT20 cells transfected with rat brain cannabinoid receptor. J. Neurosci., 1995, 15, 6552-6561
4. Pan, X.; Ikeda, S.R.; Lewis, D.L. Rat brain cannabinoid receptor modulates N-type Ca2+ channels in a neuronal expression system. Mol. Pharmacol., 1996, 49, 707-714 (Pubitemid 26117156)
5. Glass, M.; Dragunow, M.; Faull, R.L. Cannabinoid receptors in the human brain: a detailed anatomical and quantitative autoradiographic study in the fetal, neonatal and adult human brain. Neuroscience, 1997, 77, 299-318.
6. Westlake, T.M.; Howlett, A.C.; Bonner, T.I.; Matsuda, L.A.; Herkenham, M. Cannabinoid receptor binding and messenger RNA expression in human brain: an in vitro receptor autoradiography and in situ hybridization histochemistry study of normal aged and Alzheimer's brains. Neuroscience, 1994, 63, 637-652 (Pubitemid 24360219)
7. Pertwee, R.G. Pharmacology of cannabinoid CB1 and CB2 receptors. Pharmacol. Ther., 1997, 74, 129-180
8. Gerard, C.M.; Mollereau, C.; Vassart, G.; Parmentier, M. Molecular cloning of a human cannabinoid receptor which is also expressed in testis. Biochem. J., 1991, 279 ( Pt 1), 129-134
9. Straiker, A.J.; Maguire, G.; Mackie, K.; Lindsey, J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest. Ophthalmol. Vis. Sci., 1999, 40, 2442-2448 (Pubitemid 29418406)
10. Schuel, H.; Chang, M.C.; Burkman, L.J.; Picone, R.P.; Makriyannis, A.; Zimmerman, A.M.; Zimmerman, S., Cannabinoid Receptors in Sperm in Marijuana and Medicine. 1999, Humana Press: Totowa. p. 335-345
11. Wright, K.; Rooney, N.; Feeney, M.; Tate, J.; Robertson, D.; Welham, M.; Ward, S. Differential expression of cannabinoid receptors in the human colon: cannabinoids promote epithelial wound healing. Gastroenterology, 2005, 129, 437-453 (Pubitemid 41096632)
12. Ishac, E.J.; Jiang, L.; Lake, K.D.; Varga, K.; Abood, M.E.; Kunos, G. Inhibition of exocytotic noradrenaline release by presynaptic cannabinoid CB1 receptors on peripheral sympathetic nerves. Br. J. Pharmacol., 1996, 118, 2023-2028 (Pubitemid 26292572)
13. Roche, R.; Hoareau, L.; Bes-Houtmann, S.; Gonthier, M.P.; Laborde, C.; Baron, J.F.; Haffaf, Y.; Cesari, M.; Festy, F. Presence of the cannabinoid receptors, CB1 and CB2, in human omental and subcutaneous adipocytes. Histochem. Cell Biol., 2006, 126, 177-187
14. Bouaboula, M.; Rinaldi, M.; Carayon, P.; Carillon, C.; Delpech, B.; Shire, D.; Le Fur, G.; Casellas, P. Cannabinoid-receptor expression in human leukocytes. Eur. J. Biochem., 1993, 214, 173-180
15. Galiegue, S.; Mary, S.; Marchand, J.; Dussossoy, D.; Carriere, D.; Carayon, P.; Bouaboula, M.; Shire, D.; Le Fur, G.; Casellas, P. Expression of central and peripheral cannabinoid receptors in human immune tissues and leukocyte subpopulations. Eur. J. Biochem., 1995, 232, 54-61.
16. Rice, W.; Shannon, J.M.; Burton, F.; Fiedeldey, D. Expression of a brain-type cannabinoid receptor (CB1) in alveolar Type II cells in the lung: regulation by hydrocortisone. Eur. J. Pharmacol., 1997, 327, 227-232 (Pubitemid 27248550)
17. Devane, W.A.; Dysarz, F.A., 3rd; Johnson, M.R.; Melvin, L.S.; Howlett, A.C. Determination and characterization of a cannabinoid receptor in rat brain. Mol. Pharmacol., 1988, 34, 605-613
18. Melvin, L.S.; Milne, G.M.; Johnson, M.R.; Wilken, G.H.; Howlett, A.C. Structure-activity relationships defining the ACD-tricyclic cannabinoids: cannabinoid receptor binding and analgesic activity. Drug Des. Discov., 1995, 13, 155-166
19. D'Ambra, T.E.; Estep, K.G.; Bell, M.R.; Eissenstat, M.A.; Josef, K.A.; Ward, S.J.; Haycock, D.A.; Baizman, E.R.; Casiano, F.M.; Beglin, N.C.; Chippari, S. M.; Grego, J.D.; Kullnig, R.K.; Daley, G.T. Conformationally restrained analogues of pravadoline: nanomolar potent, enantioselective, (aminoalkyl)indole agonists of the cannabinoid receptor. J. Med. Chem., 1992, 35, 124-135
20. Ward, S.J.; Baizman, E.; Bell, M.; Childers, S.; D'Ambra, T.; Eissenstat, M.; Estep, K.; Haycock, D.; Howlett, A.; Luttinger, D.; Miller, M.; Pacheco, M. Aminoalkylindoles (AAIs): a new route to the cannabinoid receptor? NIDA Res. Monogr., 1991, 105, 425-426
21. Compton, D.R.; Gold, L.H.; Ward, S.J.; Balster, R.L.; Martin, B.R. Aminoalkylindole analogs: cannabimimetic activity of a class of compounds structurally distinct from delta 9-tetrahydrocannabinol. J. Pharmacol. Exp. Ther., 1992, 263, 1118-1126
22. Reggio, P.H.; Panu, A.M.; Miles, S. Characterization of a region of steric interference at the cannabinoid receptor using the active analog approach. J. Med. Chem., 1993, 36, 1761-1771 (Pubitemid 23191304)
23. Rinaldi-Carmona, M.; Barth, F.; Heaulme, M.; Shire, D.; Calandra, B.; Congy, C.; Martinez, S.; Maruani, J.; Neliat, G.; Caput, D.; et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor. FEBS Lett., 1994, 350, 240-244 (Pubitemid 24268029)
24. Bouaboula, M.; Perrachon, S.; Milligan, L.; Canat, X.; Rinaldi-Carmona, M.; Portier, M.; Barth, F.; Calandra, B.; Pecceu, F.; Lupker, J.; Maffrand, J.P.; Le Fur, G.; Casellas, P. A selective inverse agonist for central cannabinoid receptor inhibits mitogen-activated protein kinase activation stimulated by insulin or insulin-like growth factor 1. Evidence for a new model of receptor/ligand interactions. J. Biol. Chem., 1997, 272, 22330-22339 (Pubitemid 27382869)
25. 2+ currents by reversal of tonic CB1 cannabinoid receptor activity. Mol. Pharmacol., 1998, 54, 1064-1072
26. Meschler, J.P.; Kraichely, D.M.; Wilken, G.H.; Howlett, A.C. Inverse agonist properties of N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide HCl (SR141716A) and 1-(2-chlorophenyl)-4-cyano-5-(4-methoxyphenyl)-1H-pyrazole-3-carboxyl ic acid phenylamide (CP-272871) for the CB(1) cannabinoid receptor. Biochem. Pharmacol., 2000, 60, 1315-1323
27. Felder, C.C.; Joyce, K.E.; Briley, E.M.; Glass, M.; Mackie, K.P.; Fahey, K.J.; Cullinan, G.J.; Hunden, D.C.; Johnson, D.W.; Chaney, M.O.; Koppel, G.A.; Brownstein, M. LY320135, a novel cannabinoid CB1 receptor antagonist, unmasks coupling of the CB1 receptor to stimulation of cAMP accumulation. J. Pharmacol. Exp. Ther., 1998, 284, 291-297 (Pubitemid 28109558)
28. Ross, R.A.; Brockie, H.C.; Fernando, S.R.; Saha, B.; Razdan, R.K.; Pertwee, R.G. Comparison of cannabinoid binding sites in guinea-pig forebrain and small intestine. Br. J. Pharmacol., 1998, 125, 1345-1351
29. LoVerme, J.; Duranti, A.; Tontini, A.; Spadoni, G.; Mor, M.; Rivara, S.; Stella, N.; Xu, C.; Tarzia, G.; Piomelli, D. Synthesis and characterization of a peripherally restricted CB1 cannabinoid antagonist, URB447, that reduces feeding and body-weight gain in mice. Bioorg. Med. Chem. Lett., 2009, 19, 639-643
30. Stoit, A.R.; Lange, J.H.M.; den Hartog, A.P.; Ronken, E.; Tipker, K.; van Stuivenberg, H.H.; Dijksman, J.A.R.; Wals, H.C.; Kruse, C.G. Design, synthesis and biological activity of rigid cannabinoid CB1 receptor antagonists. Chem. Pharm. Bull., 2002, 50, 1109-1113
31. Lange, J.H.; Coolen, H.K.; van Stuivenberg, H.H.; Dijksman, J.A.; Herremans, A.H.; Ronken, E.; Keizer, H.G.; Tipker, K.; McCreary, A.C.; Veerman, W.; Wals, H.C.; Stork, B.; Verveer, P.C.; den Hartog, A.P.; de Jong, N.M.; Adolfs, T.J.; Hoogendoorn, J.; Kruse, C.G. Synthesis, biological properties, and molecular modeling investigations of novel 3,4-diarylpyrazolines as potent and selective CB(1) cannabinoid receptor antagonists. J. Med. Chem., 2004, 47, 627-643
32. Lee, S.H.; Seo, H.J.; Lee, S.H.; Jung, M.E.; Park, J.H.; Park, H.J.; Yoo, J.; Yun, H.; Na, J.; Kang, S.Y.; Song, K.S.; Kim, M.A.; Chang, C.H.; Kim, J.; Lee, J. Biarylpyrazolyl oxadiazole as potent, selective, orally bioavailable cannabinoid-1 receptor antagonists for the treatment of obesity. J. Med. Chem., 2008, 51, 7216-7233
33. Heimann, A.S.; Gomes, I.; Dale, C.S.; Pagano, R.L.; Gupta, A.; de Souza, L.L.; Luchessi, A.D.; Castro, L.M.; Giorgi, R.; Rioli, V.; Ferro, E.S.; Devi, L.A. Hemopressin is an inverse agonist of CB1 cannabinoid receptors. Proc. Natl. Acad. Sci. U.S.A., 2007, 104, 20588-20593
34. Jagerovic, N.; Fernandez-Fernandez, C.; Goya, P. CB1 cannabinoid antagonists: structure-activity relationships and potential therapeutic applications. Curr. Top. Med. Chem., 2008, 8, 205-230 (Pubitemid 351795770)
35. Devane, W.A.; Hanus, L.; Breuer, A.; Pertwee, R.G.; Stevenson, L.A.; Griffin, G.; Gibson, D.; Mandelbaum, A.; Etinger, A.; Mechoulam, R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science, 1992, 258, 1946-1949
36. Hanus, L.; Gopher, A.; Almog, S.; Mechoulam, R. Two new unsaturated fatty acid ethanolamides in brain that bind to the cannabinoid receptor. J. Med. Chem., 1993, 36, 3032-3034 (Pubitemid 23315410)
37. Mechoulam, R.; Ben-Shabat, S.; Hanus, L.; Ligumsky, M.; Kaminski, N.E.; Schatz, A.R.; Gopher, A.; Almog, S.; Martin, B.R.; Compton, D.R.; Pertwee, R. G.; Griffin, G.; Bayewitch, M.; Barg, J.; Vogel, Z. Identification of an endogenous 2-monoglyceride, present in canine gut, that binds to cannabinoid receptors. Biochem. Pharmacol., 1995, 50, 83-90.
38. Stella, N.; Schweitzer, P.; Piomelli, D. A second endogenous cannabinoid that modulates long-term potentiation. Nature, 1997, 388, 773-778
39. Hanus, L.; Abu-Lafi, S.; Fride, E.; Breuer, A.; Vogel, Z.; Shalev, D.E.; Kustanovich, I.; Mechoulam, R. 2-arachidonyl glyceryl ether, an endogenous agonist of the cannabinoid CB1 receptor. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 3662-3665 (Pubitemid 32249827)
40. Oka, S.; Tsuchie, A.; Tokumura, A.; Muramatsu, M.; Suhara, Y.; Takayama, H.; Waku, K.; Sugiura, T. Ether-linked analogue of 2-arachidonoylglycerol (noladin ether) was not detected in the brains of various mammalian species. J. Neurochem., 2003, 85, 1374-1381 (Pubitemid 36702550)
41. Bezuglov, V.; Bobrov, M.; Gretskaya, N.; Gonchar, A.; Zinchenko, G.; Melck, D.; Bisogno, T.; Di Marzo, V.; Kuklev, D.; Rossi, J.C.; Vidal, J.P.; Durand, T. Synthesis and biological evaluation of novel amides of polyunsaturated fatty acids with dopamine. Bioorg. Med. Chem. Lett., 2001, 11, 447-449
42. Bisogno, T.; Melck, D.; Bobrov, M.; Gretskaya, N.M.; Bezuglov, V.V.; De Petrocellis, L.; Di Marzo, V. N-acyl-dopamines: novel synthetic CB(1) cannabinoid-receptor ligands and inhibitors of anandamide inactivation with cannabimimetic activity in vitro and in vivo. Biochem. J., 2000, 351 Pt 3, 817-824
43. Porter, A.C.; Sauer, J.M.; Knierman, M.D.; Becker, G.W.; Berna, M.J.; Bao, J.; Nomikos, G.G.; Carter, P.; Bymaster, F.P.; Leese, A.B.; Felder, C.C. Characterization of a novel endocannabinoid, virodhamine, with antagonist activity at the CB1 receptor. J. Pharmacol. Exp. Ther., 2002, 301, 1020-1024 (Pubitemid 34595094)
44. Munro, S.; Thomas, K.L.; Abu-Shaar, M. Molecular characterization of a peripheral receptor for cannabinoids. Nature, 1993, 365, 61-65 (Pubitemid 23305569)
45. Bouaboula, M.; Poinot-Chazel, C.; Marchand, J.; Canat, X.; Bourrie, B.; Rinaldi-Carmona, M.; Calandra, B.; Le Fur, G.; Casellas, P. Signaling pathway associated with stimulation of CB2 peripheral cannabinoid receptor. Involvement of both mitogen-activated protein kinase and induction of Krox-24 expression. Eur. J. Biochem., 1996, 237, 704-711 (Pubitemid 126443878)
46. Bouaboula, M.; Desnoyer, N.; Carayon, P.; Combes, T.; Casellas, P. Gi protein modulation induced by a selective inverse agonist for the peripheral cannabinoid receptor CB2: implication for intracellular signalization cross-regulation. Mol. Pharmacol., 1999, 55, 473-480 (Pubitemid 29128103)
47. Sanchez, M.G.; Ruiz-Llorente, L.; Sanchez, A.M.; Diaz-Laviada, I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal, 2003, 15, 851-859 (Pubitemid 36776659)
48. Guzman, M.; Galve-Roperh, I.; Sanchez, C. Ceramide: a new second messenger of cannabinoid action. Trends Pharmacol. Sci., 2001, 22, 19-22.
49. Howlett, A.C.; Barth, F.; Bonner, T.I.; Cabral, G.; Casellas, P.; Devane, W.A.; Felder, C.C.; Herkenham, M.; Mackie, K.; Martin, B.R.; Mechoulam, R.; Pertwee, R.G. International Union of Pharmacology. XXVII. Classification of cannabinoid receptors. Pharmacol. Rev., 2002, 54, 161-202.
50. Benito, C.; Nunez, E.; Tolon, R.M.; Carrier, E.J.; Rabano, A.; Hillard, C.J.; Romero, J. Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains. J. Neurosci., 2003, 23, 11136-11141 (Pubitemid 37548949)
51. Ashton, J.C.; Glass, M. The Cannabinoid CB2 receptor as a target for inflammation-dependent neurodegeneration. Curr. Neuropharmacol., 2007, 5, 73-80. (Pubitemid 47019422)
52. Onaivi, E.S.; Ishiguro, H.; Gong, J.P.; Patel, S.; Meozzi, P.A.; Myers, L.; Perchuk, A.; Mora, Z.; Tagliaferro, P.A.; Gardner, E.; Brusco, A.; Akinshola, B.E.; Hope, B.; Lujilde, J.; Inada, T.; Iwasaki, S.; Macharia, D.; Teasenfitz, L.; Arinami, T.; Uhl, G.R. Brain neuronal CB2 cannabinoid receptors in drug abuse and depression: from mice to human subjects. PLoS One, 2008, 3, e1640.
53. Van Sickle, M.D.; Duncan, M.; Kingsley, P.J.; Mouihate, A.; Urbani, P.; Mackie, K.; Stella, N.; Makriyannis, A.; Piomelli, D.; Davison, J.S.; Marnett, L.J.; Di Marzo, V.; Pittman, Q.J.; Patel, K.D.; Sharkey, K.A. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science, 2005, 310, 329-332
54. Buckley, N.E.; McCoy, K.L.; Mezey, E.; Bonner, T.; Zimmer, A.; Felder, C.C.; Glass, M. Immunomodulation by cannabinoids is absent in mice deficient for the cannabinoid CB(2) receptor. Eur. J. Pharmacol., 2000, 396, 141-149 (Pubitemid 30265571)
55. Massi, P.; Fuzio, D.; Vigano, D.; Sacerdote, P.; Parolaro, D. Relative involvement of cannabinoid CB(1) and CB(2) receptors in the Delta(9)- tetrahydrocannabinol-induced inhibition of natural killer activity. Eur. J. Pharmacol., 2000, 387, 343-347 (Pubitemid 30067837)
56. Jorda, M.A.; Verbakel, S.E.; Valk, P.J.; Vankan-Berkhoudt, Y.V.; Maccarrone, M.; Finazzi-Agro, A.; Lowenberg, B.; Delwel, R. Hematopoietic cells expressing the peripheral cannabinoid receptor migrate in response to the endocannabinoid 2-arachidonoylglycerol. Blood, 2002, 99, 2786-2793 (Pubitemid 34525366)
57. Kishimoto, S.; Gokoh, M.; Oka, S.; Muramatsu, M.; Kajiwara, T.; Waku, K.; Sugiura, T. 2-arachidonoylglycerol induces the migra tion of HL-60 cells differentiated into macrophage-like cells and human peripheral blood monocytes through the cannabinoid CB2 receptor-dependent mechanism. J. Biol. Chem., 2003, 278, 24469-24475 (Pubitemid 37548598)
58. Franklin, A.; Stella, N. Arachidonylcyclopropylamide increases microglial cell migration through cannabinoid CB2 and abnormalcannabidiol-sensitive receptors. Eur. J. Pharmacol., 2003, 474, 195-198 (Pubitemid 37281448)
59. Kishimoto, S.; Kobayashi, Y.; Oka, S.; Gokoh, M.; Waku, K.; Sugiura, T. 2-Arachidonoylglycerol, an endogenous cannabinoid receptor ligand, induces accelerated production of chemokines in HL-60 cells. J. Biochem. (Tokyo), 2004, 135, 517-524 (Pubitemid 38660939)
60. McCoy, K.L.; Matveyeva, M.; Carlisle, S.J.; Cabral, G.A. Cannabinoid inhibition of the processing of intact lysozyme by macrophages: evidence for CB2 receptor participation. J. Pharmacol. Exp. Ther., 1999, 289, 1620-1625
61. Idris, A.I.; van 't Hof, R.J.; Greig, I.R.; Ridge, S.A.; Baker, D.; Ross, R.A.; Ralston, S.H. Regulation of bone mass, bone loss and osteoclast activity by cannabinoid receptors. Nat. Med., 2005, 11, 774-779
62. Ofek, O.; Karsak, M.; Leclerc, N.; Fogel, M.; Frenkel, B.; Wright, K.; Tam, J.; Attar-Namdar, M.; Kram, V.; Shohami, E.; Mechoulam, R.; Zimmer, A.; Bab, I. Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc. Natl. Acad. Sci. U.S.A., 2006, 103, 696-701. (Pubitemid 43153088)
63. Song, Z.H.; Slowey, C.A.; Hurst, D.P.; Reggio, P.H. The difference between the CB(1) and CB(2) cannabinoid receptors at position 5.46 is crucial for the selectivity of WIN55212-2 for CB(2). Mol. Pharmacol., 1999, 56, 834-840
64. Sugiura, T.; Kondo, S.; Sukagawa, A.; Nakane, S.; Shinoda, A.; Itoh, K.; Yamashita, A.; Waku, K. 2-Arachidonoylglycerol: a possible endogenous cannabinoid receptor ligand in brain. Biochem. Biophys. Res. Commun., 1995, 215, 89-97.
65. Huffman, J.W.; Liddle, J.; Yu, S.; Aung, M.M.; Abood, M.E.; Wiley, J.L.; Martin, B.R. 3-(1′,1′-Dimethylbutyl)-1-deoxy-delta8-THC and related compounds: synthesis of selective ligands for the CB2 receptor. Bioorg. Med. Chem., 1999, 7, 2905-2914 (Pubitemid 30105863)
66. Huffman, J.W.; Bushell, S.M.; Miller, J.R.; Wiley, J.L.; Martin, B.R. 1-Methoxy-, 1-deoxy-11-hydroxy- and 11-Hydroxy-1-methoxy-Delta(8)- tetrahydrocannabinols: new selective ligands for the CB(2) receptor. Bioorg. Med. Chem., 2002, 10, 4119-4129 (Pubitemid 36164713)
67. Gareau, Y.; Dufresne, C.; Gallant, M.; Rochette, C.; Sawyer, N.; Slipetz, D.M.; Tremblay, N.; Weech, P.K.; Metters, K.M.; Labelle, M. Structure activity relationships of tetrahydrocannabinol analogues on human cannabinoid receptors. Bioorg. Med. Chem., 1996, 6, 186-194 (Pubitemid 26045675)
68. Huffman, J.W.; Yu, S.; Showalter, V.; Abood, M.E.; Wiley, J.L.; Compton, D.R.; Martin, B.R.; Bramblett, R.D.; Reggio, P.H. Synthesis and pharmacology of a very potent cannabinoid lacking a phenolic hydroxyl with high affinity for the CB2 receptor. J. Med. Chem., 1996, 39, 3875-3877
69. Rinaldi-Carmona, M.; Barth, F.; Millan, J.; Derocq, J.M.; Casellas, P.; Congy, C.; Oustric, D.; Sarran, M.; Bouaboula, M.; Calandra, B.; Portier, M.; Shire, D.; Breliere, J.C.; Le Fur, G.L. SR 144528, the first potent and selective antagonist of the CB2 cannabinoid receptor. J. Pharmacol. Exp. Ther., 1998, 284, 644-650
70. Iwamura, H.; Suzuki, H.; Ueda, Y.; Kaya, T.; Inaba, T. In vitro and in vivo pharmacological characterization of JTE-907, a novel selective ligand for cannabinoid CB2 receptor. J. Pharmacol. Exp. Ther., 2001, 296, 420-425 (Pubitemid 32112468)
71. Ross, R.A.; Brockie, H.C.; Stevenson, L.A.; Murphy, V.L.; Templeton, F.; Makriyannis, A.; Pertwee, R.G. Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656, and AM630. Br. J. Pharmacol., 1999, 126, 665-672
72. Lavey, B.J.; Kozlowski, J.A.; Hipkin, R.W.; Gonsiorek, W.; Lundell, D.J.; Piwinski, J.J.; Narula, S.; Lunn, C.A. Triaryl bis-sulfones as a new class of cannabinoid CB2 receptor inhibitors: identification of a lead and initial SAR studies. Bioorg. Med. Chem. Lett., 2005, 15, 783-786
73. Shankar, B.B.; Lavey, B.J.; Zhou, G.; Spitler, J.A.; Tong, L.; Rizvi, R.; Yang, D.Y.; Wolin, R.; Kozlowski, J.A.; Shih, N.Y.; Wu, J.; Hipkin, R.W.; Gonsiorek, W.; Lunn, C.A. Triaryl bis-sulfones as cannabinoid-2 receptor ligands: SAR studies. Bioorg. Med. Chem. Lett., 2005, 15, 4417-4420
74. Sawzdargo, M.; Nguyen, T.; Lee, D.K.; Lynch, K.R.; Cheng, R.; Heng, H.H.; George, S.R.; O'Dowd, B.F. Identification and cloning of three novel human G protein-coupled receptor genes GPR52, PsiGPR53 and GPR55: GPR55 is extensively expressed in human brain. Brain Res Mol Brain Res, 1999, 64, 193-198
75. Brown, A.; Wise, A. Identification of modulators of GPR55 activity. WO0186305. 2003, GlaxoSmithKline: USPTO.
76. Drmota, T.; Greasley, P.; Groblewski, T., Screening assays for cannabinoid-ligand type modulators of GPR55. 2004, Astrazeneca: USA.
77. Brown, A.; Ueno, S.; Suen, K.; Dowell, S.; Wise, A. Molecular identification of GPR55 as a third G-protein coupled receptor responsive to cannabinoid ligands. in 2005 Symposium of the Cannabinoids. 2005. Clearwater, FL: International Cannabinoid Research Society.
78. Sjogren, S.; Ryberg, E.; Lindblom, A.; Larsson, N.; Astrand, A.; Hjorth, S.; Andersson, A.; Groblewski, T.; Greasley, P. A new receptor for cannabinoid ligands. in 2005 Symposium on the Cannabinoids. 2005. Clearwater, FA: International Cannabinoid Research Society.
79. Skaper, S.D.; Buriani, A.; Toso, R.D.; Petrelli, L.; Romanello, S.; Facci, L.; Leon, A. The ALIAmide palmitoylethanolamide and cannabinoids, but not anandamide, are protective in a delayed post-glutamate paradigm of excitotoxic death in cerebellar granule neurons. Proc. Natl. Acad. Sci. USA, 1996, 93, 3984-3989 (Pubitemid 26146721)
80. Jaggar, S.; Sellaturay, S.; Rice, A. The endogenous cannabinoid anandamide, but not the CB2 ligand palmitoylethanolamide, prevents the viscero-visceral hyper-reflexia associated with inflammation of the rat urinary bladder. Neurosci. Lett., 1998, 253, 123-126 (Pubitemid 28430638)
81. Ryberg, E.; Larsson, N.; Sjogren, S.; Hjorth, S.; Hermansson, N.O.; Leonova, J.; Elebring, T.; Nilsson, K.; Drmota, T.; Greasley, P.J. The orphan receptor GPR55 is a novel cannabinoid receptor. Br. J. Pharmacol., 2007, 152, 1092-1101
82. Johns, D.G.; Behm, D.J.; Walker, D.J.; Ao, Z.; Shapland, E.M.; Daniels, D.A.; Riddick, M.; Dowell, S.; Staton, P.C.; Green, P.; Shabon, U.; Bao, W.; Aiyar, N.; Yue, T.L.; Brown, A.J.; Morrison, A.D.; Douglas, S.A. The novel endocannabinoid receptor GPR55 is activated by atypical cannabinoids but does not mediate their vasodilator effects. Br. J. Pharmacol., 2007, 152, 825-831
83. Lauckner, J.E.; Jensen, J.B.; Chen, H.Y.; Lu, H.C.; Hille, B.; Mackie, K. GPR55 is a cannabinoid receptor that increases intracellular calcium and inhibits M current. Proc. Natl. Acad. Sci. U.S.A., 2008, 105, 2699-2704 (Pubitemid 351520576)
84. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362, 928-934
85. Oka, S.; Nakajima, K.; Yamashita, A.; Kishimoto, S.; Sugiura, T. Identification of GPR55 as a lysophosphatidylinositol receptor. Biochem. Biophys. Res. Commun., 2007, 362, 928-934
86. Oka, S.; Toshida, T.; Maruyama, K.; Nakajima, K.; Yamashita, A.; Sugiura, T. 2-Arachidonoyl-sn-glycero-3-phosphoinositol: a possible natural ligand for GPR55. J. Biochem., 2009, 145, 13-20.
87. Kapur, A.; Zhao, P.; Sharir, H.; Bai, Y.; Caron, M.G.; Barak, L.S.; Abood, M.E. Atypical responsiveness of the orphan receptor GPR55 to cannabinoid ligands. J. Biol. Chem., 2009, 284, 29817-29827
88. Palczewski, K.; Kumasaka, T.; Hori, T.; Behnke, C.A.; Motoshima, H.; Fox, B.A.; Le Trong, I.; Teller, D.C.; Okada, T.; Stenkamp, R.E.; Yamamoto, M.; Miyano, M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science, 2000, 289, 739-745 (Pubitemid 30650186)
89. Li, J.; Edwards, P.C.; Burghammer, M.; Villa, C.; Schertler, G.F. Structure of bovine rhodopsin in a trigonal crystal form. J. Mol. Biol., 2004, 343, 1409-1438 (Pubitemid 39387834)
90. Okada, T.; Fujiyoshi, Y.; Silow, M.; Navarro, J.; Landau, E.M.; Shichida, Y. Functional role of internal water molecules in rhodopsin revealed by X-ray crystallography. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 5982-5987 (Pubitemid 34493251)
91. Okada, T.; Sugihara, M.; Bondar, A.N.; Elstner, M.; Entel, P.; Buss, V. The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. J. Mol. Biol., 2004, 342, 571-583 (Pubitemid 39149759)
92. Rasmussen, S.G.; Choi, H.J.; Rosenbaum, D.M.; Kobilka, T.S.; Thian, F.S.; Edwards, P.C.; Burghammer, M.; Ratnala, V.R.; Sanishvili, R.; Fischetti, R.F.; Schertler, G.F.; Weis, W.I.; Kobilka, B.K. Crystal structure of the human beta(2) adrenergic G-protein-coupled receptor. Nature, 2007, 450, 383-387
93. Cherezov, V.; Rosenbaum, D.M.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Kuhn, P.; Weis, W.I.; Kobilka, B.K.; Stevens, R.C. High-Resolution Crystal Structure of an Engineered Human {beta}2-Adrenergic G Protein Coupled Receptor. Science, 2007, .
94. Rosenbaum, D.M.; Cherezov, V.; Hanson, M.A.; Rasmussen, S.G.; Thian, F.S.; Kobilka, T.S.; Choi, H.J.; Yao, X.J.; Weis, W.I.; Stevens, R.C.; Kobilka, B.K. GPCR Engineering Yields High-Resolution Structural Insights into {beta}2 Adrenergic Receptor Function. Science, 2007, .
95. Warne, T.; Serrano-Vega, M.J.; Baker, J.G.; Moukhametzianov, R.; Edwards, P.C.; Henderson, R.; Leslie, A.G.; Tate, C.G.; Schertler, G.F. Structure of a beta1-adrenergic G-protein-coupled receptor. Nature, 2008, 454, 486-491
96. Jaakola, V.P.; Griffith, M.T.; Hanson, M.A.; Cherezov, V.; Chien, E.Y.; Lane, J.R.; Ijzerman, A.P.; Stevens, R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science, 2008, 322, 1211-1217
97. Farrens, D.; Altenbach, C.; Ynag, K.; Hubbell, W.; Khorana, H. Requirement of rigid-body motion of transmembrane helices for light activation of rhodopsin. Science, 1996, 274, 768-770 (Pubitemid 26398253)
98. Ghanouni, P.; Steenhuis, J.J.; Farrens, D.L.; Kobilka, B.K. Agonist-induced conformational changes in the G-protein-coupling domain of the beta 2 adrenergic receptor. Proc. Natl. Acad. Sci. U.S.A., 2001, 98, 5997-6002.
99. Lin, S.W.; Sakmar, T.P. Specific tryptophan UV-absorbance changes are probes of the transition of rhodopsin to its active state. Biochemistry, 1996, 35, 11149-11159
100. Javitch, J.A.; Fu, D.; Liapakis, G.; Chen, J. Constitutive activation of the beta2 adrenergic receptor alters the orientation of its sixth membrane-spanning segment. J. Biol. Chem., 1997, 272, 18546-18549 (Pubitemid 27318192)
101. Jensen, A.D.; Guarnieri, F.; Rasmussen, S.G.; Asmar, F.; Ballesteros, J.A.; Gether, U. Agonist-induced conformational changes at the cytoplasmic side of transmembrane segment 6 in the beta 2 adrenergic receptor mapped by site-selective fluorescent labeling. J. Biol. Chem., 2001, 276, 9279-9290 (Pubitemid 37385512)
102. Nakanishi, J.; Takarada, T.; Yunoki, S.; Kikuchi, Y.; Maeda, M. FRET-based monitoring of conformational change of the beta2 adrenergic receptor in living cells. Biochem. Biophys. Res. Commun., 2006, 343, 1191-1196
103. Wess, J. G-protein-coupled receptors: Molecular mechanisms involved in receptor activation and selectivity of G-protein recognition. FASEB J., 1997, 11, 346-354 (Pubitemid 27193939)
104. Katona, I.; Freund, T.F. Endocannabinoid signaling as a synaptic circuit breaker in neurological disease. Nat. Med., 2008, 14, 923-930
105. Piomelli, D. The molecular logic of endocannabinoid signalling. Nat. Rev. Neurosci., 2003, 4, 873-884
106. Di Marzo, V. Targeting the endocannabinoid system: to enhance or reduce? Nat. Rev. Drug Discov., 2008, 7, 438-455 (Pubitemid 351649182)
107. Di Marzo, V. The endocannabinoid system: its general strategy of action, tools for its pharmacological manipulation and potential therapeutic exploitation. Pharmacol. Res., 2009, 60, 77-84.
108. Levenes, C.; Daniel, H.; Soubrie, P.; Crepel, F. Cannabinoids decrease excitatory synaptic transmission and impair long-term depression in rat cerebellar Purkinje cells. J. Physiol., 1998, 510(Pt 3), 867-879 (Pubitemid 28401291)
109. Hoffman, A.F.; Lupica, C.R. Mechanisms of cannabinoid inhibition of GABA(A) synaptic transmission in the hippocampus. J. Neurosci., 2000, 20, 2470-2479 (Pubitemid 30220334)
110. Kreitzer, A.C.; Regehr, W.G. Retrograde inhibition of presynaptic calcium influx by endogenous cannabinoids at excitatory synapses onto Purkinje cells. Neuron, 2001, 29, 717-727
111. Ohno-Shosaku, T.; Maejima, T.; Kano, M. Endogenous cannabinoids mediate retrograde signals from depolarized postsynaptic neurons to presynaptic terminals. Neuron, 2001, 29, 729-738 (Pubitemid 32323945)
112. Wilson, R.I.; Nicoll, R.A. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature, 2001, 410, 588-592
113. Takahashi, K.A.; Linden, D.J. Cannabinoid receptor modulation of synapses received by cerebellar Purkinje cells. J. Neurophysiol., 2000, 83, 1167-1180
114. Mackie, K. Signaling via CNS cannabinoid receptors. Mol. Cell Endocrinol., 2008, 286, S60-5.
115. Dinh, T.P.; Carpenter, D.; Leslie, F.M.; Freund, T.F.; Katona, I.; Sensi, S.L.; Kathuria, S.; Piomelli, D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. U.S.A., 2002, 99, 10819-10824 (Pubitemid 36044549)
116. Okamoto, Y.; Wang, J.; Morishita, J.; Ueda, N. Biosynthetic pathways of the endocannabinoid anandamide. Chem. Biodivers., 2007, 4, 1842-1857
117. Nyilas, R.; Dudok, B.; Urban, G.M.; Mackie, K.; Watanabe, M.; Cravatt, B.F.; Freund, T.F.; Katona, I. Enzymatic machinery for endocannabinoid biosynthesis associated with calcium stores in glutamatergic axon terminals. J. Neurosci., 2008, 28, 1058-1063 (Pubitemid 351186335)
118. Di Marzo, V.; Fontana, A.; Cadas, H.; Schinelli, S.; Cimino, G.; Schwartz, J.C.; Piomelli, D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature, 1994, 372, 686-691
119. Piomelli, D.; Beltramo, M.; Giuffrida, A.; Stella, N. Endogenous cannabinoid signaling. Neurobiol. Dis., 1998, 5, 462-473
120. Kaczocha, M.; Glaser, S.T.; Deutsch, D.G. Identification of intracellular carriers for the endocannabinoid anandamide. Proc. Natl. Acad. Sci. U.S.A., 2009, 106, 6375-6380
121. Di Marzo, V.; Melck, D.; Bisogno, T.; De Petrocellis, L. Endocannabinoids: endogenous cannabinoid receptor ligands with neuromodulatory action. Trends Neurosci., 1998, 21, 521-528 (Pubitemid 28555694)
122. Bracey, M.H.; Hanson, M.A.; Masuda, K.R.; Stevens, R.C.; Cravatt, B.F. Structural adaptations in a membrane enzyme that terminates endocannabinoid signaling. Science, 2002, 298, 1793-1796
123. Giang, D.K.; Cravatt, B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. U.S.A., 1997, 94, 2238-2242 (Pubitemid 27136858)
124. Arreaza, G.; Deutsch, D.G. Deletion of a proline-rich region and a transmembrane domain in fatty acid amide hydrolase. FEBS Lett., 1999, 454, 57-60.
125. Berglund, B.A.; Boring, D.L.; Wilken, G.H.; Makriyannis, A.; Howlett, A.C.; Lin, S. Structural requirements for arachidonylethanolamide interaction with CB1 and CB2 cannabinoid receptors: pharmacology of the carbonyl and ethanolamide groups. Prostaglandins Leukot Essent Fatty Acids, 1998, 59, 111-118
126. Pinto, J.C.; Potie, F.; Rice, K.C.; Boring, D.; Johnson, M.R.; Evans, D.M.; Wilken, G.H.; Cantrell, C.H.; Howlett, A.C. Cannabinoid receptor binding and agonist activity of amides and esters of arachidonic acid. Mol. Pharmacol., 1994, 46, 516-522
127. Lin, S.; Khanolkar, A.D.; Fan, P.; Goutopoulos, A.; Qin, C.; Papahadjis, D.; Makriyannis, A. Novel analogues of arachidonylethanolamide (anandamide): affinities for the CB1 and CB2 cannabinoid receptors and metabolic stability. J. Med. Chem., 1998, 41, 5353-5361 (Pubitemid 29031319)
128. Ng, E.W.; Aung, M.M.; Abood, M.E.; Martin, B.R.; Razdan, R.K. Unique analogues of anandamide: arachidonyl ethers and carbamates and norarachidonyl carbamates and ureas. J. Med. Chem., 1999, 42, 1975-1981
129. Parkkari, T.; Savinainen, J.R.; Rauhala, A.L.; Tolonen, T.L.; Nevalainen, T.; Laitinen, J.T.; Gynther, J.; Jarvinen, T. Synthesis and CB1 receptor activities of novel arachidonyl alcohol derivatives. Bioorg. Med. Chem. Lett., 2004, 14, 3231-3234
130. El Fangour, S.; Balas, L.; Rossi, J.C.; Fedenyuk, A.; Gretskaya, N.; Bobrov, M.; Bezuglov, V.; Hillard, C.J.; Durand, T. Hemisynthesis and preliminary evaluation of novel endocannabinoid analogues. Bioorg. Med. Chem. Lett., 2003, 13, 1977-1980 (Pubitemid 36638393)
131. Parkkari, T.; Savinainen, J.R.; Raitio, K.H.; Saario, S.M.; Matilainen, L.; Sirvio, T.; Laitinen, J.T.; Nevalainen, T.; Niemi, R.; Jarvinen, T. Synthesis, cannabinoid receptor activity, and enzymatic stability of reversed amide derivatives of arachidonoyl ethanolamide. Bioorg. Med. Chem., 2006, 14, 5252-5258
132. Abadji, V.; Lin, S.; Taha, G.; Griffin, G.; Stevenson, L.A.; Pertwee, R.G.; Makriyannis, A. (R)-methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem., 1994, 37, 1889-1893
133. Adams, I.B.; Ryan, W.; Singer, M.; Razdan, R.K.; Compton, D.R.; Martin, B.R. Pharmacological and behavioral evaluation of alkylated anandamide analogs. Life Sci., 1995, 56, 2041-2048
134. Goutopoulos, A.; Fan, P.; Khanolkar, A.D.; Xie, X.Q.; Lin, S.; Makriyannis, A. Stereochemical selectivity of methanandamides for the CB1 and CB2 cannabinoid receptors and their metabolic stability. Bioorg. Med. Chem., 2001, 9, 1673-1684 (Pubitemid 32651902)
135. Sheskin, T.; Hanus, L.; Slager, J.; Vogel, Z.; Mechoulam, R. Structural requirements for binding of anandamide-type compounds to the brain cannabinoid receptor. J. Med. Chem., 1997, 40, 659-667 (Pubitemid 27102571)
136. Hillard, C.J.; Manna, S.; Greenberg, M.J.; DiCamelli, R.; Ross, R.A.; Stevenson, L.A.; Murphy, V.; Pertwee, R.G.; Campbell, W.B. Synthesis and characterization of potent and selective agonists of the neuronal cannabinoid receptor (CB1). J. Pharmacol. Exp. Ther., 1999, 289, 1427-1433 (Pubitemid 29246674)
137. Adams, I.B.; Ryan, W.; Singer, M.; Thomas, B.F.; Compton, D.R.; Razdan, R.K.; Martin, B.R. Evaluation of cannabinoid receptor binding and in vivo activities for anandamide analogs. J. Pharmacol. Exp. Ther., 1995, 273, 1172-1181
138. Lang, W.; Qin, C.; Lin, S.; Khanolkar, A.D.; Goutopoulos, A.; Fan, P.; Abouzid, K.; Meng, Z.; Biegel, D.; Makriyannis, A. Substrate specificity and stereoselectivity of rat brain microsomal anandamide amidohydrolase. J. Med. Chem., 1999, 42, 896-902. (Pubitemid 29136178)
139. Khanolkar, A.D.; Abadji, V.; Lin, S.; Hill, W.A.; Taha, G.; Abouzid, K.; Meng, Z.; Fan, P.; Makriyannis, A. Head group analogs of arachidonylethanolamide, the endogenous cannabinoid ligand. J. Med. Chem., 1996, 39, 4515-4519 (Pubitemid 26359410)
140. Edgemond, W.S.; Hillard, C.J.; Falck, J.R.; Kearn, C.S.; Campbell, W.B. Human platelets and polymorphonuclear leukocytes synthesize oxygenated derivatives of arachidonylethanolamide (anandamide): their affinities for cannabinoid receptors and pathways of inactivation. Mol. Pharmacol., 1998, 54, 180-188
141. Edgemond, W.S.; Campbell, W.B.; Hillard, C.J. The binding of novel phenolic derivatives of anandamide to brain cannabinoid receptors. Prostaglandins Leukot. Essent. Fatty Acids, 1995, 52, 83-86
142. Barnett-Norris, J.; Hurst, D.P.; Lynch, D.L.; Guarnieri, F.; Makriyannis, A.; Reggio, P.H. Conformational memories and the endocannabinoid binding site at the cannabinoid CB1 receptor. J. Med. Chem., 2002, 45, 3649-3659
143. Seltzman, H.H.; Fleming, D.N.; Thomas, B.F.; Gilliam, A.F.; McCallion, D.S.; Pertwee, R.G.; Compton, D.R.; Martin, B.R. Synthesis and pharmacological comparison of dimethylheptyl and pentyl analogs of anandamide. J. Med. Chem., 1997, 40, 3626-3634
144. Ryan, W.J.; Banner, W.K.; Wiley, J.L.; Martin, B.R.; Razdan, R.K. Potent anandamide analogs: the effect of changing the length and branching of the end pentyl chain. J. Med. Chem., 1997, 40, 3617-3625
145. Berglund, B.A.; Boring, D.L.; Howlett, A.C. Investigation of structural analogs of prostaglandin amides for binding to and activation of CB1 and CB2 cannabinoid receptors in rat brain and human tonsils. Adv. Exp. Med. Biol., 1999, 469, 527-533
146. Berglund, B.A.; Fleming, P.R.; Rice, K.C.; Shim, J.Y.; Welsh, W.J.; Howlett, A.C. Development of a novel class of monocyclic and bicyclic alkyl amides that exhibit CB1 and CB2 cannabinoid receptor affinity and receptor activation. Drug Des. Discov., 2000, 16, 281-294
147. Barnett-Norris, J.; Guarnieri, F.; Hurst, D.P.; Reggio, P.H. Exploration of biologically relevant conformations of anandamide, 2-arachidonylglycerol, and their analogues using conformational memories. J. Med. Chem., 1998, 41, 4861-4872
148. 2+ in neuroblastoma x glioma hybrid NG108-15 cells. Biochem. Biophys. Res. Commun., 1996, 229, 58-64.
149. 2+ transient in NG108-15 cells. J. Biochem. (Tokyo), 1997, 122, 890-895
150. Sugiura, T.; Kodaka, T.; Nakane, S.; Miyashita, T.; Kondo, S.; Suhara, Y.; Takayama, H.; Waku, K.; Seki, C.; Baba, N.; Ishima, Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem., 1999, 274, 2794-2801 (Pubitemid 29075361)
151. Parkkari, T.; Myllymaki, M.; Savinainen, J.R.; Saario, S.M.; Castillo-Melendez, J.A.; Laitinen, J.T.; Nevalainen, T.; Koskinen, A.M.; Jarvinen, T. Alpha-methylated derivatives of 2-arachidonoyl glycerol: synthesis, CB1 receptor activity, and enzymatic stability. Bioorg. Med. Chem. Lett., 2006, 16, 2437-2440
152. Parkkari, T.; Salo, O.M.; Huttunen, K.M.; Savinainen, J.R.; Laitinen, J.T.; Poso, A.; Nevalainen, T.; Jarvinen, T. Synthesis and CB1 receptor activities of dimethylheptyl derivatives of 2-arachidonoyl glycerol (2-AG) and 2-arachidonyl glyceryl ether (2-AGE). Bioorg. Med. Chem., 2006, 14, 2850-2858
153. Sugiura, T.; Kondo, S.; Kishimoto, S.; Miyashita, T.; Nakane, S.; Kodaka, T.; Suhara, Y.; Takayama, H.; Waku, K. Evidence that 2-arachidonoylglycerol but not N-palmitoylethanolamine or anandamide is the physiological ligand for the cannabinoid CB2 receptor. Comparison of the agonistic activities of various cannabinoid receptor ligands in HL-60 cells. J. Biol. Chem., 2000, 275, 605-612 (Pubitemid 30039024)
154. Suhara, Y.; Oka, S.; Kittaka, A.; Takayama, H.; Waku, K.; Sugiura, T. Synthesis and biological evaluation of several structural analogs of 2-arachidonoylglycerol, an endogenous cannabinoid receptor ligand. Bioorg. Med. Chem., 2007, 15, 854-867
155. Vadivel, S.K.; Vardarajan, S.; Duclos, R.I., Jr.; Wood, J.T.; Guo, J.; Makriyannis, A. Conformationally constrained analogues of 2- arachidonoylglycerol. Bioorg. Med. Chem. Lett,. 2007, 17, 5959-5963
156. Rabinovich, A.L.; Ripatti, P.O. On the conformational, physical properties and function of polyunsaturated acylchains. Biochim. Biophys. Acta, 1991, 1085, 53-56
157. Rich, M.R. Conformational analysis of arachidonic and related fatty acids using molecular dynamics simulations. Biochim. Biophys. Acta, 1993, 1178, 87-96.
158. Reggio, P.H.; Traore, H. Conformational requirements for endocannabinoid interaction with the cannabinoid receptors, the anandamide transporter and fatty acid amidohydrolase. Chem Phys Lipids, 2000, 108, 15-35.
159. Thomas, B.F.; Adams, I.B.; Mascarella, S.W.; Martin, B.R.; Razdan, R.K. Structure-activity analysis of anandamide analogs: relationship to a cannabinoid pharmacophore. J. Med. Chem., 1996, 39, 471-479
160. Tong, W.; Collantes, E.R.; Welsh, W.J.; Berglund, B.A.; Howlett, A.C. Derivation of a pharmacophore model for anandamide using constrained conformational searching and comparative molecular field analysis. J. Med. Chem., 1998, 41, 4207-4215
161. Di Marzo, M.; Casapullo, A.; Bifulco, G.; Cimino, P.; Ligresti, A.; Di Marzo, V.; Riccio, R.; Gomez-Paloma, L. Synthesis, conformational analysis and CB1 binding affinity of hairpin-like anandamide pseudopeptide mimetics. J. Pept. Sci., 2006, 12, 575-591
162. Tian, X.; Guo, J.; Yao, F.; Yang, D.P.; Makriyannis, A. The conformation, location, and dynamic properties of the endocannabinoid ligand anandamide in a membrane bilayer. J. Biol. Chem., 2005, 280, 29788-29795 (Pubitemid 41177056)
163. Barnett-Norris, J.; Hurst, D.P.; Buehner, K.; Ballesteros, J.A.; Guarnieri, F.; Reggio, P.H. Agonist alkyl tail interaction with cannabinoid CB1 receptor V6.43/I6.46 groove induces a Helix 6 active conformation. Int. J. Quantum Chem., 2002, 88, 76-86.
164. Lynch, D.L.; Reggio, P.H. Cannabinoid CB1 receptor recognition of endocannabinoids via the lipid bilayer: molecular dynamics simulations of CB1 transmembrane helix 6 and anandamide in a phospholipid bilayer. J. Comput. Aided Mol. Des., 2006, 20, 495-509.
165. Picone, R.P.; Khanolkar, A.D.; Xu, W.; Ayotte, L.A.; Thakur, G.A.; Hurst, D.P.; Abood, M.E.; Reggio, P.H.; Fournier, D.J.; Makriyannis, A. (-)-7′-Isothiocyanato-11-hydroxy-1′,1′- dimethylheptylhexahydrocannabinol (AM841), a high-affinity electrophilic ligand, interacts covalently with a cysteine in helix six and activates the CB1 cannabinoid receptor. Mol. Pharmacol., 2005, 68, 1623-1635
166. Pei, Y.; Mercier, R.W.; Anday, J.K.; Thakur, G.A.; Zvonok, A.M.; Hurst, D.; Reggio, P.H.; Janero, D.R.; Makriyannis, A. Ligand-binding architecture of human CB2 cannabinoid receptor: evidence for receptor subtype-specific binding motif and modeling GPCR activation. Chem. Biol., 2008, 15, 1207-1219
167. Kimura, T.; Cheng, K.; Rice, K.C.; Gawrisch, K. Location, structure, and dynamics of the synthetic cannabinoid ligand CP-55,940 in lipid bilayers. Biophys. J., 2009, 96, 4916-4924
168. Li, C.; Xu, W.; Vadivel, S.K.; Fan, P.; Makriyannis, A. High affinity electrophilic and photoactivatable covalent endocannabinoid probes for the CB1 receptor. J. Med. Chem., 2005, 48, 6423-6429 (Pubitemid 41428994)
169. McAllister, S.D.; Rizvi, G.; Anavi-Goffer, S.; Hurst, D.P.; Barnett-Norris, J.; Lynch, D.L.; Reggio, P.H.; Abood, M.E. An aromatic microdomain at the cannabinoid CB(1) receptor constitutes an agonist/inverse agonist binding region. J. Med. Chem., 2003, 46, 5139-5152
170. Hurst, D.P.; Lynch, D.L.; Barnett-Norris, J.; Hyatt, S.M.; Seltzman, H.H.; Zhong, M.; Song, Z.H.; Nie, J.; Lewis, D.; Reggio, P.H. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4-dichlorophenyl)-4-methyl-1H-p yrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol., 2002, 62, 1274-1287
171. Hurst, D.; Umejiego, U.; Lynch, D.; Seltzman, H.; Hyatt, S.; Roche, M.; McAllister, S.; Fleischer, D.; Kapur, A.; Abood, M.; Shi, S.; Jones, J.; Lewis, D.; Reggio, P. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: Importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J. Med. Chem., 2006, in press, .
172. Kapur, A.; Hurst, D.P.; Fleischer, D.; Whitnell, R.; Thakur, G.A.; Makriyannis, A.; Reggio, P.H.; Abood, M.E. Mutation studies of Ser7.39 and Ser2.60 in the human CB1 cannabinoid receptor: evidence for a serine-induced bend in CB1 transmembrane helix 7. Mol. Pharmacol., 2007, 71, 1512-1524
173. Fay, J.F.; Dunham, T.D.; Farrens, D.L. Cysteine residues in the human cannabinoid receptor: only C257 and C264 are required for a functional receptor, and steric bulk at C386 impairs antagonist SR141716A binding. Biochemistry, 2005, 44, 8757-8769
174. Shire, D.; Calandra, B.; Delpech, M.; Dumont, X.; Kaghad, M.; Le Fur, G.; Caput, D.; Ferrara, P. Structural features of the central cannabinoid CB1 receptor involved in the binding of the specific CB1 antagonist SR 141716A. J. Biol. Chem., 1996, 271, 6941-6946 (Pubitemid 26104790)
175. Ahn, K.H.; Bertalovitz, A.C.; Mierke, D.F.; Kendall, D.A. Dual role of the second extracellular loop of the cannabinoid receptor 1: ligand binding and receptor localization. Mol. Pharmacol., 2009, 76, 833-842
176. McAllister, S.D.; Hurst, D.P.; Barnett-Norris, J.; Lynch, D.; Reggio, P.H.; Abood, M.E. Structural mimicry in class A G protein-coupled receptor rotamer toggle switches: the importance of the F3.36(201)/W6.48(357) interaction in cannabinoid CB1 receptor activation. J. Biol. Chem., 2004, 279, 48024-48037
177. Murphy, J.W.; Kendall, D.A. Integrity of extracellular loop 1 of the human cannabinoid receptor 1 is critical for high-affinity binding of the ligand CP 55,940 but not SR 141716A. Biochem. Pharmacol., 2003, 65, 1623-1631
178. Song, Z.H.; Bonner, T.I. A lysine residue of the cannabinoid receptor is critical for receptor recognition by several agonists but not WIN55212-2. Mol. Pharmacol., 1996, 49, 891-896
179. Chin, C.; Lucas-Lenard, J.; Abadji, V.; Kendall, D.A. Ligand Binding and Modulation of Cyclic AMP Levels Depend on the Chemical Nature of Residue 192 of the Human Cannabinoid Receptor 1. J. Neurochem, 1998, 70, 366-373
180. Shen, C.P.; Xiao, J.C.; Armstrong, H.; Hagmann, W.; Fong, T.M. F200A substitution in the third transmembrane helix of human cannabinoid CB1 receptor converts AM2233 from receptor agonist to inverse agonist. Eur. J. Pharmacol., 2006, 531, 41-46
181. Chin, C.N.; Murphy, J.W.; Huffman, J.W.; Kendall, D.A. The third transmembrane helix of the cannabinoid receptor plays a role in the selectivity of aminoalkylindoles for CB2, peripheral cannabinoid receptor. J. Pharmacol. Exp. Ther., 1999, 291, 837-844
182. Rhee, M.H. Functional role of serine residues of transmembrane dopamin VII in signal transduction of CB2 cannabinoid receptor. J. Vet. Sci., 2002, 3, 185-191
183. Tao, Q.; McAllister, S.D.; Andreassi, J.; Nowell, K.W.; Cabral, G.A.; Hurst, D.P.; Bachtel, K.; Ekman, M.C.; Reggio, P.H.; Abood, M.E. Role of a conserved lysine residue in the peripheral cannabinoid receptor (CB2): evidence for subtype specificity. Mol. Pharmacol., 1999, 55, 605-613
184. Gouldson, P.; Calandra, B.; Legoux, P.; Kerneis, A.; Rinaldi-Carmona, M.; Barth, F.; Le Fur, G.; Ferrara, P.; Shire, D. Mutational analysis and molecular modelling of the antagonist SR 144528 binding site on the human cannabinoid CB(2) receptor. Eur. J. Pharmacol., 2000, 401, 17-25. (Pubitemid 30479807)
185. Shire, D.; Calandra, B.; Bouaboula, M.; Barth, F.; Rinaldi-Carmona, M.; Casellas, P.; Ferrara, P. Cannabinoid receptor interactions with the antagonists SR 141716A and SR 144528. Life Sci., 1999, 65, 627-635 (Pubitemid 29362768)
186. Shim, J.Y.; Welsh, W.J.; Howlett, A.C. Homology model of the CB1 cannabinoid receptor: Sites critical for nonclassical cannabinoid agonist interaction. Biopolymers, 2003, 71, 169-189
187. Shim, J.Y.; Howlett, A.C. WIN55212-2 docking to the CB1 cannabinoid receptor and multiple pathways for conformational induction. J. Chem. Inf. Model., 2006, 46, 1286-1300
188. Tuccinardi, T.; Ferrarini, P.L.; Manera, C.; Ortore, G.; Saccomanni, G.; Martinelli, A. Cannabinoid CB2/CB1 selectivity. Receptor modeling and automated docking analysis. J. Med. Chem., 2006, 49, 984-994 (Pubitemid 43221646)
189. Padgett, L.W.; Howlett, A.C.; Shim, J.Y. Binding mode prediction of conformationally restricted anandamide analogs within the CB1 receptor. J. Mol. Signal., 2008, 3, 5.
190. Salo, O.M.; Lahtela-Kakkonen, M.; Gynther, J.; Jarvinen, T.; Poso, A. Development of a 3D model for the human cannabinoid CB1 receptor. J. Med. Chem., 2004, 47, 3048-3057 (Pubitemid 38702701)
191. Montero, C.; Campillo, N.E.; Goya, P.; Paez, J.A. Homology models of the cannabinoid CB1 and CB2 receptors. A docking analysis study. Eur. J. Med. Chem., 2005, 40, 75-83.
192. Xie, X.Q.; Chen, J.Z.; Billings, E.M. 3D structural model of the G-protein-coupled cannabinoid CB2 receptor. Proteins, 2003, 53, 307-319 (Pubitemid 37193825)
193. Salo, O.M.; Raitio, K.H.; Savinainen, J.R.; Nevalainen, T.; Lahtela-Kakkonen, M.; Laitinen, J.T.; Jarvinen, T.; Poso, A. Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. J. Med. Chem., 2005, 48, 7166-7171 (Pubitemid 41743629)
194. Chen, J.Z.; Wang, J.; Xie, X.Q. GPCR structure-based virtual screening approach for CB2 antagonist search. J. Chem. Inf. Model., 2007, 47, 1626-1637
195. Dainese, E.; Oddi, S.; Maccarrone, M. Lipid-mediated dimerization of beta2-adrenergic receptor reveals important clues for cannabinoid receptors. Cell Mol. Life Sci., 2008, 65, 2277-2279
196. Shim, J.Y. Transmembrane helical domain of the cannabinoid CB1 receptor. Biophys. J., 2009, 96, 3251-3262
197. Hurst DP, L.D., Barnett-Norris J, Hyatt SM, Seltzman HH, Zhong M, Song ZH, Nie J, Lewis D, Reggio PH. N-(piperidin-1-yl)-5-(4-chlorophenyl)-1-(2,4- dichlorophenyl)-4-methyl-1H-pyrazole-3-carboxamide (SR141716A) interaction with LYS 3.28(192) is crucial for its inverse agonism at the cannabinoid CB1 receptor. Mol. Pharmacol., 2002, 62, 1274-1287 (Pubitemid 35403823)
198. Hurst, D.; Umejiego, U.; Lynch, D.; Seltzman, H.; Hyatt, S.; Roche, M.; McAllister, S.; Fleischer, D.; Kapur, A.; Abood, M.; Shi, S.; Jones, J.; Lewis, D.; Reggio, P. Biarylpyrazole inverse agonists at the cannabinoid CB1 receptor: importance of the C-3 carboxamide oxygen/lysine3.28(192) interaction. J. Med. Chem., 2006, 49, 5969-5987 (Pubitemid 44484943)
199. Zhang, R.; Hurst, D.P.; Barnett-Norris, J.; Reggio, P.H.; Song, Z.H. Cysteine 2.59(89) in the second transmembrane domain of human CB2 receptor is accessible within the ligand binding crevice: evidence for possible CB2 deviation from a rhodopsin template. Mol. Pharmacol., 2005, 68, 69-83.
200. Guarnieri, F.; Weinstein, H. Conformational memories and the Exploration of biologically relevant peptide conformations: an illustration for the gonadotropin-releasing hormone. J. Amer. Chem. Soc., 1996, 118, 5580-5589 (Pubitemid 26233645)
201. Whitnell, R.M.; Hurst, D.P.; Reggio, P.H.; Guarnieri, F. Conformational memories with variable bond angles. J. Comput. Chem., 2007, .
202. Barnett-Norris, J.; Hurst, D.P.; Reggio, P.H. The influence of cannabinoid receptor second extracellular loop conformation on the binding of CP55940. in 2003 Symposium on the Cannabinoids. 2003. Cornwall, Ontario.: Internatiobnal Cannabinoid Research Society.
203. Hassan, S.A.; Mehler, E.L.; Weinstein, H., Structure calculation of protein segments connecting domains with defined secondary structure: A simulated annealing Monte Carlo combined with biased scaled collective variables technique, in Computational Methods for Macromolecules: Challenges and Applications, T. Schlick and H.H. Gan, Editors. 2002, Springer Verlag: New York. p. 197-231.
204. Hassan, S.A.; Guarnieri, F.; Mehler, E.L. A General treatment of solvent effects based on screened coulomb potentials. J. Phys. Chem. B, 2000, 104, 6478-6489
205. Hassan, S.A.; Guarnieri, F.; Mehler, E.L. Characterization of hydrogen bonding in a continuum solvent model. J. Phys. Chem. B, 2000, 104, 6490-6498
206. Bonechi, C.; Brizzi, A.; Brizzi, V.; Francoli, M.; Donati, A.; Rossi, C. Conformational analysis of N-arachidonylethanolamide (anandamide) using nuclear magnetic resonance and theoretical calculations. Magn. Reson. Chem., 2001, 39, 432-437 (Pubitemid 33310970)
207. Brizzi, A.; Brizzi, V.; Cascio, M.G.; Corelli, F.; Guida, F.; Ligresti, A.; Maione, S.; Martinelli, A.; Pasquini, S.; Tuccinardi, T.; Di Marzo, V. New resorcinol-anandamide "hybrids" as potent cannabinoid receptor ligands endowed with antinociceptive activity in vivo. J. Med. Chem., 2009, 52, 2506-2514
208. Salo, O.M.; Savinainen, J.R.; Parkkari, T.; Nevalainen, T.; Lahtela-Kakkonen, M.; Gynther, J.; Laitinen, J.T.; Jarvinen, T.; Poso, A. 3D-QSAR studies on cannabinoid CB1 receptor agonists: Gprotein activation as biological data. J. Med. Chem., 2006, 49, 554-566 (Pubitemid 43157488)
209. Lynch, D.L.; Hurst, D.P.; Reggio, P.H.; Grossfield, A.; Gawrisch, K.; Feller, S.; Pitman, M. Atomic Level Description of GPCR Activation Revealed by Microsecond Timescale MD. in Biophysical Society. 2009. Boston, MA.
210. Lynch, D.L.; Reggio, P.H. Molecular dynamics simulations of the endocannabinoid, N-arachidonoylethanolamine (anandamide) in a phospholipid bilayer: probing structure and dynamics. J. Med. Chem., 2005, 48, 4824-4833
211. Nebane, N.M.; Hurst, D.P.; Carrasquer, C.A.; Qiao, Z.; Reggio, P.H.; Song, Z.H. Residues accessible in the binding-site crevice of transmembrane helix 6 of the CB2 cannabinoid receptor. Biochemistry, 2008, 47, 13811-13821